View More View Less
  • 1 Semmelweis University Institue of Medical Microbiology Budapest Hungary
  • | 2 National Center for Epidemiology Budapest Hungary
  • | 3 Semmelweis University Institute of Laboratory Medicine, Diagnostic Laboratory of Clinical Microbiology Budapest Hungary
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $784.00

In this study antibiotic combinations for multidrug-resistant Klebsiella pneumoniae strains were investigated. The study included a colistin-susceptible and a colistin-resistant KPC-2 producing K. pneumoniae ST258 strains isolated in 2008 and 2009 during an outbreak in Hungary. Antibiotic combinations were analyzed by checkerboard technique and fractional inhibitory concentration indices were calculated. The following antibiotics were tested: ceftazidime, cefotaxime, ceftriaxone, ampicillin, imipenem, ertapenem, amikacin, tobramycin, ciprofloxacin, levofloxacin, moxifloxacin, rifampicin, polymyxin B and colistin. Combinations including 0.25 μg/ml colistin plus 1 μg/ml rifampicin, 0.25 μg/ml polymyxin B plus 1 μg/ml rifampicin, 1 μg/ml imipenem plus 2 μg/ml tobramycin, were found synergistic.These in vitro synergistic combinations suggest potential therapeutical options against infections caused by KPC-2 producing, multidrug-resistant K. pneumoniae ST258.

  • Boucher, H.W., Talbot, G.H., Bradley, J.S., Edwards, J.E., Gilbert, D., Rice, L.B., Scheld, M., Spellberg, B., Bartlett, J.: Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48, 1–12 (2009).

    Bartlett J. , 'Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America ' (2009 ) 48 Clin Infect Dis : 1 -12.

    • Search Google Scholar
  • Hirsch, E.B., Tam, V.H.: Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): An emerging cause of multidrug-resistant infection. J Antimicrob Chemother 65, 1119–1125 (2010).

    Tam V.H. , 'Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): An emerging cause of multidrug-resistant infection ' (2010 ) 65 J Antimicrob Chemother : 1119 -1125.

    • Search Google Scholar
  • Zavascki, A.P., Goldani, L.Z., Li, J., Nation, R.L.: Polymyxin B for the treatment of multidrug-resistant pathogens: A critical review. J Antimicrob Chemother 60, 1206–1215 (2007).

    Nation R.L. , 'Polymyxin B for the treatment of multidrug-resistant pathogens: A critical review ' (2007 ) 60 J Antimicrob Chemother : 1206 -1215.

    • Search Google Scholar
  • Falagas, M.E., Rafailidis, P.I., Ioannidou, E., Alexiou, V.G., Matthaiou, D.K., Karageorgopoulos, D.E., Kapaskelis, A., Nikita, D., Michalopoulos, A.: Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: Aretrospective cohort study of 258 patients. Int J Antimicrob Agents 35, 194–199 (2010).

    Michalopoulos A. , 'Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: Aretrospective cohort study of 258 patients ' (2010 ) 35 Int J Antimicrob Agents : 194 -199.

    • Search Google Scholar
  • Bergen, P.J., Landersdorfer, C.B., Lee, H.J., Li, J., Nation, R.L.: ’Old’ antibiotics for emerging multidrug-resistant bacteria. Curr Opin Infect Dis 25, 626–633 (2012).

    Nation R.L. , '’Old’ antibiotics for emerging multidrug-resistant bacteria ' (2012 ) 25 Curr Opin Infect Dis : 626 -633.

    • Search Google Scholar
  • Kontopoulou, K., Protonotariou, E., Vasilakos, K., Kriti, M., Koteli, A., Antoniadou, E., Sofianou, D.: Hospital outbreak caused by Klebsiella pneumoniae producing KPC-2 b-lactamase resistant to colistin. J Hosp Infect 76, 70–73 (2010).

    Sofianou D. , 'Hospital outbreak caused by Klebsiella pneumoniae producing KPC-2 b-lactamase resistant to colistin ' (2010 ) 76 J Hosp Infect : 70 -73.

    • Search Google Scholar
  • Urban, C., Tiruvury, H., Mariano, N., Colon-Urban, R., Rahal, J.J.: Polymyxin-resistant clinical isolates of Escherichia coli. Antimicrob Agents Chemother 55, 388–389 (2011).

    Rahal J.J. , 'Polymyxin-resistant clinical isolates of Escherichia coli ' (2011 ) 55 Antimicrob Agents Chemother : 388 -389.

    • Search Google Scholar
  • Marchaim, D., Chopra, T., Pogue, J.M., Perez, F., Hujer, A.M., Rudin, S., Endimiani, A., Navon-Venezia, S., Hothi, J., Slim, J., Blunden, C., Shango, M., Lephart, P.R., Salimnia, H., Reid, D., Moshos, J., Hafeez, W., Bheemreddy, S., Chen, T.Y., Dhar, S., Bonomo, R.A., Kaye, K.S.: Outbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan. Antimicrob Agents Chemother 55, 593–599 (2011).

    Kaye K.S. , 'Outbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan ' (2011 ) 55 Antimicrob Agents Chemother : 593 -599.

    • Search Google Scholar
  • Mammina, C., Bonura, C., Di Bernardo, F., Aleo, A., Fasciana, T., Sodano, C., Saporito, M.A., Verde, M.S., Tetamo, R., Palma, D.M.: Ongoing spread of colistin-resistant Klebsiella pneumoniae in different wards of an acute general hospital, Italy, June to December 2011. Euro Surveill 17 (2012).

  • Capone, A., Giannella, M., Fortini, D., Giordano, A., Meledandri, M., Ballardini, M., Venditti, M., Bordi, E., Capozzi, D., Balice, M.P., Tarasi, A., Parisi, G., Lappa, A., Carattoli, A., Petrosillo, N.: High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect 19, E23–E30 (2013).

    Petrosillo N. , 'High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality ' (2013 ) 19 Clin Microbiol Infect : E23 -E30.

    • Search Google Scholar
  • Falagas, M.E., Rafailidis, P.I., Matthaiou, D.K.: Resistance to polymyxins: Mechanisms, frequency and treatment options. Drug Resist Updat 13, 132–138 (2010).

    Matthaiou D.K. , 'Resistance to polymyxins: Mechanisms, frequency and treatment options ' (2010 ) 13 Drug Resist Updat : 132 -138.

    • Search Google Scholar
  • Kline, T., Trent, M.S., Stead, C.M., Lee, M.S., Sousa, M.C., Felise, H.B., Nguyen, H.V., Miller, S.I.: Synthesis of and evaluation of lipid A modification by 4-substituted 4-deoxy arabinose analogs as potential inhibitors of bacterial polymyxin resistance. Bioorg Med Chem Lett 18, 1507–1510 (2008).

    Miller S.I. , 'Synthesis of and evaluation of lipid A modification by 4-substituted 4-deoxy arabinose analogs as potential inhibitors of bacterial polymyxin resistance ' (2008 ) 18 Bioorg Med Chem Lett : 1507 -1510.

    • Search Google Scholar
  • Pournaras, S., Vrioni, G., Neou, E., Dendrinos, J., Dimitroulia, E., Poulou, A., Tsakris, A.: Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. Int J Antimicrob Agents 37, 244–247 (2011).

    Tsakris A. , 'Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay ' (2011 ) 37 Int J Antimicrob Agents : 244 -247.

    • Search Google Scholar
  • Zarkotou, O., Pournaras, S., Tselioti, P., Dragoumanos, V., Pitiriga, V., Ranellou, K., Prekates, A., Themeli-Digalaki, K., Tsakris, A.: Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 17, 1798–1803 (2011).

    Tsakris A. , 'Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment ' (2011 ) 17 Clin Microbiol Infect : 1798 -1803.

    • Search Google Scholar
  • Qureshi, Z.A., Paterson, D.L., Potoski, B.A., Kilayko, M.C., Sandovsky, G., Sordillo, E., Polsky, B., Adams-Haduch, J.M., Doi, Y.: Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: Superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 56, 2108–2113 (2012).

    Doi Y. , 'Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: Superiority of combination antimicrobial regimens ' (2012 ) 56 Antimicrob Agents Chemother : 2108 -2113.

    • Search Google Scholar
  • Lee, G.C., Burgess, D.S.: Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: A review of published case series and case reports. Ann Clin Microbiol Antimicrob 11, 32 (2012).

    Burgess D.S. , 'Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: A review of published case series and case reports ' (2012 ) 11 Ann Clin Microbiol Antimicrob : 32 -.

    • Search Google Scholar
  • Vidaillac, C., Benichou, L., Duval, R.E.: In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother 56, 4856–4861 (2012).

    Duval R.E. , 'In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates ' (2012 ) 56 Antimicrob Agents Chemother : 4856 -4861.

    • Search Google Scholar
  • Tóth, Á., Damjanova, I., Puskás, E., Jánvári, L., Farkas, M., Dobák, A., Böröcz, K., Pászti, J.: Emergence of a colistin-resistant KPC-2-producing Klebsiella pneumoniae ST258 clone in Hungary. Eur J Clin Microbiol Infect Dis 29, 765–769 (2010).

  • European Committee on antimicrobial susceptibility testing (Eucast) documents. Document version 3.0 2013-01-01. http://eucast.org/clinical_breakpoints

  • Krogstad, D.J., Moellering, R.C.: Antimicrobial Combinations. In: Lorian, V. (ed.): Antibiotics in Laboratory Medicine, 2nd Edition. Baltimore: Williams & Wilkins, 1986, pp. 537–595.

  • The Sanford Guide To Antimicrobial Therapy, 42nd Edition. Sperryville: Antimicrobial Therapy, Inc., 2012.

  • Leclercq, R., Cantón, R., Brown, D.F., Giske, C.G., Heisig, P., Macgowan, A.P., Mouton, J.W., Nordmann, P., Rodloff, A.C., Rossolini, G.M., Soussy, C.J., Steinbakk, M., Winstanley, T.G., Kahlmeter, G.: EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect 19, 1141–160 (2013).

    Kahlmeter G. , 'EUCAST expert rules in antimicrobial susceptibility testing ' (2013 ) 19 Clin Microbiol Infect : 1141 -160.

    • Search Google Scholar
  • Tumbarello, M., Viale, P., Viscoli, C., Trecarichi, E.M., Tumietto, F., Marchese, A., Spanu, T., Ambretti, S., Ginocchio, F., Cristini, F., Losito, A.R., Tedeschi, S., Cauda, R., Bassetti, M.: Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: Importance of combination therapy. Clin Infect Dis 55, 943–950 (2012).

    Bassetti M. , 'Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: Importance of combination therapy ' (2012 ) 55 Clin Infect Dis : 943 -950.

    • Search Google Scholar
  • Urban, C., Mariano, N., Rahal, J.J.: In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Antimicrob Agents Chemother 54, 2732–2734 (2010).

    Rahal J.J. , 'In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli ' (2010 ) 54 Antimicrob Agents Chemother : 2732 -2734.

    • Search Google Scholar
  • Gomez, E., Sanchez, M., Gul, Z., Urban, C., Mariano, N., Eng, R.H., Huang, D.B., Chiang, T.: Polymyxin combination therapy and the use of serum bactericidal titers in the management of KPC-producing Klebsiella pneumoniae infections: A report of 3 cases. Case Report Med 2011, 659–669 (2011).

  • Ostenson, R.C., Fields, B.T., Nolan, C.M.: Polymyxin B and rifampin: New regimen for multiresistant Serratia marcescens infections. Antimicrob Agents Chemother 12, 655–659 (1977).

    Nolan C.M. , 'Polymyxin B and rifampin: New regimen for multiresistant Serratia marcescens infections ' (1977 ) 12 Antimicrob Agents Chemother : 655 -659.

    • Search Google Scholar
  • Giamarellos-Bourboulis, E.J., Karnesis, L., Giamarellou, H.: Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 44, 259–263 (2002).

    Giamarellou H. , 'Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia ' (2002 ) 44 Diagn Microbiol Infect Dis : 259 -263.

    • Search Google Scholar
  • Timurkaynak, F., Can, F., Azap, O.K., Demirbilek, M., Arslan, H., Karaman, S.O.: In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agents 27, 224–228 (2006).

    Karaman S.O. , 'In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units ' (2006 ) 27 Int J Antimicrob Agents : 224 -228.

    • Search Google Scholar
  • Elemam, A., Rahimian, J., Doymaz, M.: In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae. J Clin Microbiol 48, 3558–3562 (2010).

    Doymaz M. , 'In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae ' (2010 ) 48 J Clin Microbiol : 3558 -3562.

    • Search Google Scholar

 

The author instruction is available in PDF.
Please, download the file from HERE

Senior editors

Editor-in-Chief: Prof. Dóra Szabó (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Managing Editor: Dr. Béla Kocsis (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Co-editor: Dr. Andrea Horváth (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Editorial Board

  • Prof. Éva ÁDÁM (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Sebastian AMYES (Department of Medical Microbiology, University of Edinburgh, Edinburgh, UK.)
  • Dr. Katalin BURIÁN (Institute of Clinical Microbiology University of Szeged, Szeged, Hungary; Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary.)
  • Dr. Orsolya DOBAY (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Ildikó Rita DUNAY (Institute of Inflammation and Neurodegeneration, Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany; Center for Behavioral Brain Sciences (CBBS), Magdeburg, Germany)
  • Prof. Levente EMŐDY(Department of Medical Microbiology and Immunology, University of Pécs, Pécs, Hungary.)
  • Prof. Anna ERDEI (Department of Immunology, Eötvös Loránd University, Budapest, Hungary, MTA-ELTE Immunology Research Group, Eötvös Loránd University, Budapest, Hungary.)
  • Prof. Éva Mária FENYŐ (Division of Medical Microbiology, University of Lund, Lund, Sweden)
  • Prof. László FODOR (Department of Microbiology and Infectious Diseases, University of Veterinary Medicine, Budapest, Hungary)
  • Prof. József KÓNYA (Department of Medical Microbiology, University of Debrecen, Debrecen, Hungary)
  • Prof. Yvette MÁNDI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Károly MÁRIALIGETI (Department of Microbiology, Eötvös Loránd University, Budapest, Hungary)
  • Prof. János MINÁROVITS (Department of Oral Biology and Experimental Dental Research, University of Szeged, Szeged, Hungary)
  • Prof. Béla NAGY (Centre for Agricultural Research, Institute for Veterinary Medical Research, Budapest, Hungary.)
  • Prof. István NÁSZ (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Kristóf NÉKÁM (Hospital of the Hospitaller Brothers in Buda, Budapest, Hungary.)
  • Dr. Eszter OSTORHÁZI (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Rozália PUSZTAI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Peter L. RÁDY (Department of Dermatology, University of Texas, Houston, Texas, USA)
  • Prof. Éva RAJNAVÖLGYI (Department of Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary)
  • Prof. Ferenc ROZGONYI (Institute of Laboratory Medicine, Semmelweis University, Budapest, Hungary)
  • Prof. Zsuzsanna SCHAFF (2nd Department of Pathology, Semmelweis University, Budapest, Hungary)
  • Prof. Joseph G. SINKOVICS (The Cancer Institute, St. Joseph’s Hospital, Tampa, Florida, USA)
  • Prof. Júlia SZEKERES (Department of Medical Biology, University of Pécs, Pécs, Hungary.)
  • Prof. Mária TAKÁCS (National Reference Laboratory for Viral Zoonoses, National Public Health Center, Budapest, Hungary.)
  • Prof. Edit URBÁN (Department of Medical Microbiology and Immunology University of Pécs, Pécs, Hungary; Institute of Translational Medicine, University of Pécs, Pécs, Hungary.)

 

Editorial Office:
Akadémiai Kiadó Zrt.
Budafoki út 187-187, A/3, H-1117 Budapest, Hungary

Editorial Correspondence:
Acta Microbiologica et Immunologica Hungarica
Institute of Medical Microbiology
Semmelweis University
P.O. Box 370
H-1445 Budapest, Hungary
Phone: + 36 1 459 1500 ext. 56101
Fax: (36 1) 210 2959
E-mail: amih@med.semmelweis-univ.hu

 Indexing and Abstracting Services:

  • Biological Abstracts
  • BIOSIS Previews
  • CAB Abstracts
  • Chemical Abstracts
  • Global Health
  • Index Medicus
  • Index Veterinarius
  • Medline
  • Referativnyi Zhurnal
  • SCOPUS
  • Science Citation Index Expanded
2020  
Total Cites 662
WoS
Journal
Impact Factor
2,048
Rank by Immunology 145/162(Q4)
Impact Factor Microbiology 118/137 (Q4)
Impact Factor 1,904
without
Journal Self Cites
5 Year 0,671
Impact Factor
Journal  0,38
Citation Indicator  
Rank by Journal  Immunology 146/174 (Q4)
Citation Indicator  Microbiology 120/142 (Q4)
Citable 42
Items
Total 40
Articles
Total 2
Reviews
Scimago 28
H-index
Scimago 0,439
Journal Rank
Scimago Immunology and Microbiology (miscellaneous) Q4
Quartile Score Medicine (miscellaneous) Q3
Scopus 438/167=2,6
Scite Score  
Scopus General Immunology and Microbiology 31/45 (Q3)
Scite Score Rank  
Scopus 0,760
SNIP
Days from  225
sumbission
to acceptance
Days from  118
acceptance
to publication
Acceptance 19%
Rate

2019  
Total Cites
WoS
485
Impact Factor 1,086
Impact Factor
without
Journal Self Cites
0,864
5 Year
Impact Factor
1,233
Immediacy
Index
0,286
Citable
Items
42
Total
Articles
40
Total
Reviews
2
Cited
Half-Life
5,8
Citing
Half-Life
7,7
Eigenfactor
Score
0,00059
Article Influence
Score
0,246
% Articles
in
Citable Items
95,24
Normalized
Eigenfactor
0,07317
Average
IF
Percentile
7,690
Scimago
H-index
27
Scimago
Journal Rank
0,352
Scopus
Scite Score
320/161=2
Scopus
Scite Score Rank
General Immunology and Microbiology 35/45 (Q4)
Scopus
SNIP
0,492
Acceptance
Rate
16%

 

Acta Microbiologica et Immunologica Hungarica
Publication Model Online only Hybrid
Submission Fee none
Article Processing Charge 1100 EUR/article
Regional discounts on country of the funding agency World Bank Lower-middle-income economies: 50%
World Bank Low-income economies: 100%
Further Discounts Editorial Board / Advisory Board members: 50%
Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100%
Subscription Information Online subsscription: 652 EUR / 812 USD
Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content.
Purchase per Title Individual articles are sold on the displayed price.

Acta Microbiologica et Immunologica Hungarica
Language English
Size A4
Year of
Foundation
1954
Publication
Programme
2021 Volume 68
Volumes
per Year
1
Issues
per Year
4
Founder Magyar Tudományos Akadémia
Founder's
Address
H-1051 Budapest, Hungary, Széchenyi István tér 9.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 1217-8950 (Print)
ISSN 1588-2640 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Feb 2021 4 0 0
Mar 2021 9 0 0
Apr 2021 4 0 0
May 2021 7 0 0
Jun 2021 12 0 0
Jul 2021 4 0 0
Aug 2021 0 0 0